DNER and diffuse large B-cell lymphoma: Of note, a phase Ib trial of BET inhibitor RO6870810 in combination with venetoclax and rituximab in 39 patients with relapsed/refractory DLBCL revealed an overall response rate of 38.5% and complete responses in 20.5% of patients.44